Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant

References

• Pasquini M, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR Summary Slides [Internet]. 2015 [cited 2016 Aug 30]. Available from: http://www.cibmtr.org.
   Google Scholar
• Lonnqvist B, Ringden O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol. 1986;63:671–679.
   PubMed Web of Science ®Google Scholar
• Behrendt CE, Rosenthal J, Bolotin E, et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant. 2009;15:54–60.
   PubMed Web of Science ®Google Scholar
• Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol. 2006;76:414–419.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118:1402–1412.
   PubMed Web of Science ®Google Scholar
• Ito S, Pophali P, Co W, et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant. 2013;48:1313–1316.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122:1316–1324.
   PubMed Web of Science ®Google Scholar
• Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant. 2014;20:46–52.
   PubMed Web of Science ®Google Scholar
• Jang JE, Kim SJ, Cheong JW, et al. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol. 2015;94:275–282.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for acute myeloid leukemia? Blood. 2012;119:1088–1090 (author reply 1090–1081).
   PubMed Web of Science ®Google Scholar
• Travi G, Pergam SA, Xie H, et al. Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT. Biol Blood Marrow Transplant. 2009;15:758–760.
   PubMed Web of Science ®Google Scholar
• Behrendt CE, Nakamura R, Zaia J. Institution affects association between CMV seronegative graft and leukemic relapse after pediatric HCT. Biol Blood Marrow Transplant. 2010;16:133–135.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122:3359–3364.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–2438.
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Ross SR, Dührsen U, et al. Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. Leuk Lymphoma. 2017;58:822–833.
   PubMed Web of Science ®Google Scholar
• Mariotti J, Maura F, Spina F, et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:885–890.
   PubMedGoogle Scholar
• Rice GP, Schrier RD, Oldstone MB. Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA. 1984;81:6134–6138.
   PubMed Web of Science ®Google Scholar
• Takimoto Y. Improvement of adult T-cell lymphoma/leukaemia by antiviral drugs including foscarnet. Br J Haematol. 1998;102:876–877.
   PubMed Web of Science ®Google Scholar
• Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1309–1314.
   PubMed Web of Science ®Google Scholar
• Stern M, de Wreede LC, Brand R, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28:2235–2240.
   PubMed Web of Science ®Google Scholar
• Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110:2744–2748.
   PubMed Web of Science ®Google Scholar
• Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:50–58.
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–685.
   PubMed Web of Science ®Google Scholar
• Suessmuth Y, Mukherjee R, Watkins B, et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire. Blood. 2015;125:3835–3850.
   PubMed Web of Science ®Google Scholar
• Scheper W, van Dorp S, Kersting S, et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia. 2013;27:1328–1338.
   PubMed Web of Science ®Google Scholar
• Horowitz A, Guethlein LA, Nemat-Gorgani N, et al. Regulation of adaptive NK cells and CD8 T cells by HLA-C correlates with allogeneic hematopoietic cell transplantation and with cytomegalovirus reactivation. J Immunol. 2015;195:4524–4536.
   PubMed Web of Science ®Google Scholar
• Djaoud Z, David G, Bressollette C, et al. Amplified NKG2C + NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J Immunol. 2013;191:2708–2716.
   PubMed Web of Science ®Google Scholar
• Bigley AB, Rezvani K, Shah N, et al. Latent cytomegalovirus infection enhances anti-tumor cytotoxicity through accumulation of NKG2C + NK cells in healthy humans. Clin Exp Immunol. 2016;185:239–251.
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367:805–816.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Weisdorf DJ, Wang T, et al. Donor KIR B genotype improves progression-free survival of non-Hodgkin lymphoma patients receiving unrelated donor transplantation. Biol Blood Marrow Transplant. 2016;22:1602–1607.
   PubMed Web of Science ®Google Scholar
• van de Berg PJ, Heutinck KM, Raabe R, et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis. 2010;202:690–699.
   PubMed Web of Science ®Google Scholar
• Erlach KC, Bohm V, Seckert CK, et al. Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection. J Virol. 2006;80:4801–4819.
   PubMed Web of Science ®Google Scholar
• Erlach KC, Bohm V, Knabe M, et al. Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med Microbiol Immunol. 2008;197:167–178.
   PubMed Web of Science ®Google Scholar
• Erlach KC, Reddehase MJ, Podlech J. Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15. Med Microbiol Immunol. 2015;204:355–366.
   PubMed Web of Science ®Google Scholar
• Varani S, Landini MP. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae. 2011;2:6.
   PubMedGoogle Scholar
• Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119–126.
   PubMed Web of Science ®Google Scholar